Population pharmacokinetics and exposure-response analyses of polatuzumab vedotin in patients with previously untreated DLBCL from the POLARIX study

• Main Authors: Rong Deng (Author), Leonid Gibiansky (Author), Tong Lu (Author), Christopher R. Flowers (Author), Laurie H. Sehn (Author), Qi Liu (Author), Priya Agarwal (Author), Michael Z. Liao (Author), Randall Dere (Author), Calvin Lee (Author), Gabriel Man (Author), Jamie Hirata (Author), Chunze Li (Author), Dale Miles (Author)
• Format: Book
• Published: Wiley, 2024-06-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract Polatuzumab vedotin is a CD79b‐directed antibody-drug conjugate that targets B cells and delivers the cytotoxic payload monomethyl auristatin E (MMAE). The phase III POLARIX study (NCT03274492) evaluated polatuzumab vedotin in combination with rituximab, cyclophosphamide, doxorubicin, and p...